An open-label phase I, multi-center study to determine the recommended dose of the chimeric antigen receptor T-cell treatment CYAD-211 after a non-myeloablative preconditioning chemotherapy in multiple myeloma patients with relapsed or refractory disease.

×

Message d'erreur

  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 53 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 95 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
An open-label phase I, multi-center study to determine the recommended dose of the chimeric antigen receptor T-cell treatment CYAD-211 after a non-myeloablative preconditioning chemotherapy in multiple myeloma patients with relapsed or refractory disease.
Long title: 
An open-label phase I, multi-center study to determine the recommended dose of the chimeric antigen receptor T-cell treatment CYAD-211 after a non-myeloablative preconditioning chemotherapy in multiple myeloma patients with relapsed or refractory disease.
Date receipt dossier: 
2 sep 2020
EU record number: 
CYAD-211-001
EudraCT number: 
2020-001414-38
Pharmaceutical study code: 
CYAD-211
Company / Sponsor: 
Celyad
Phase: 
I
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
Multiple myeloma
Therapeutic approach: 
Immunotherapy
Genetic modification: 
BCMA-CAR and ShRNA CD3ζ
Method of transfer of nucleic acid of interest: 
Moloney murine leukemia virus
Administered biological material: 
Autologous T-cells retrovirally transduced with BCMA-CAR and ShRNA CD3ζ
Route of administration: 
Intravenous
Locations in Belgium: 
UZA, AZ Delta
Type of procedure: 
Contained use only
Current status: 
Authorized